Granted Patent
B2
US 7,425,637 · App. 11/061,336 · Granted Sep 16, 2008
N3 alkylated benzimidazole derivatives as MEK inhibitors
Assignee:
Array BioPharma Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R 1 , R 2 , R 7 , R 8 , R 9 and R 10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
Claims (1)
1. A compound which is 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide or a pharmaceutically acceptable salt thereof.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 13, 2025
From: ASTRAZENECA AB
To: ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED
Reel/Frame 072888/0633 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 037387 FRAME 0736. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Recorded Mar 10, 2016
From: ARRAY BIOPHARMA, INC.
To: ASTRAZENECA AB; ARRAY BIOPHARMA, INC.
Reel/Frame 038057/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 30, 2015
From: ARRAY BIOPHARMA, INC.
To: ASTRAZENECA AB
Reel/Frame 037387/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 18, 2005
From: WALLACE, ELI M.; LYSSIKATOS, JOSEPH P.; MARLOW, ALLISON L.; HURLEY, T. BRIAN
To: ARRAY BIOPHARMA INC.
Reel/Frame 016314/0028 →
Continuity (2)